AstraZeneca's potential $3 billion cancer pill wins early approval

LONDON (Reuters) - A new lung cancer pill from AstraZeneca , designed for patients whose disease has worsened after treatment with other therapies, won early U.S. approval on Friday, in a boost for the British drugmaker.